Immunotherapy with histamine and interleukin 2 in malignant melanoma with liver metastasis.
作者信息
Agarwala Sanjiv S, Hellstrand Kristoffer, Gehlsen Kurt, Naredi Peter
出版信息
Cancer Immunol Immunother. 2004 Sep;53(9):840-1. doi: 10.1007/s00262-004-0537-5. Epub 2004 May 4.
Abstract
摘要
相似文献
1
Immunotherapy with histamine and interleukin 2 in malignant melanoma with liver metastasis.
Cancer Immunol Immunother. 2004 Sep;53(9):840-1. doi: 10.1007/s00262-004-0537-5. Epub 2004 May 4.
2
3
Liver resection in multimodal concepts improves survival of metastatic melanoma: a single-centre case-matched control study.
Anticancer Res. 2014 Nov;34(11):6633-9.
4
Chemotherapy Foundation Symposium XVIII: Session on malignant melanoma.
Expert Opin Investig Drugs. 2001 Feb;10(2):381-5. doi: 10.1517/13543784.10.2.381.
5
Recent breakthroughs in metastatic uveal melanoma: a cause for optimism?
Future Oncol. 2018 Jun;14(14):1335-1338. doi: 10.2217/fon-2018-0116. Epub 2018 May 9.
6
Histamine: a novel approach to cancer immunotherapy.
Cancer Invest. 2000;18(4):347-55. doi: 10.3109/07357900009012178.
7
Histamine dihydrochloride and interleukin-2 in acute myeloid leukemia--background and results.
Inflamm Res. 2009 Apr;58 Suppl 1:4-8. doi: 10.1007/s00011-009-0642-1.
8
Histamine and cytokine therapy.
Acta Oncol. 1998;37(4):347-53. doi: 10.1080/028418698430566.
9
Eradication of human hepatic and pulmonary melanoma metastases in SCID mice by antibody-interleukin 2 fusion proteins.
Proc Natl Acad Sci U S A. 1996 Apr 2;93(7):2702-7. doi: 10.1073/pnas.93.7.2702.
10
[Therapy of malignant melanoma at the stage of distant metastasis].
Hautarzt. 2004 Feb;55(2):195-213. doi: 10.1007/s00105-003-0684-1.
引用本文的文献
1
In vitro and in vivo anticancer activity of aconitine on melanoma cell line B16.
Molecules. 2013 Jan 8;18(1):757-67. doi: 10.3390/molecules18010757.
2
Histamine receptors and cancer pharmacology.
Br J Pharmacol. 2010 Oct;161(4):755-67. doi: 10.1111/j.1476-5381.2010.00961.x.
3
Isolated hepatic perfusion with 200 mg melphalan for advanced noncolorectal liver metastases.
Ann Surg Oncol. 2008 Jul;15(7):1891-8. doi: 10.1245/s10434-008-9881-6. Epub 2008 May 10.
4
Monocytes and neutrophils as 'bad guys' for the outcome of interleukin-2 with and without histamine in metastatic renal cell carcinoma--results from a randomised phase II trial.
Br J Cancer. 2006 Jan 30;94(2):218-26. doi: 10.1038/sj.bjc.6602937.
5
Two randomised phase II trials of subcutaneous interleukin-2 and histamine dihydrochloride in patients with metastatic renal cell carcinoma.
Br J Cancer. 2005 Oct 3;93(7):757-62. doi: 10.1038/sj.bjc.6602768.
本文引用的文献
1
Histamine in cancer immunotherapy: a preclinical background.
Semin Oncol. 2002 Jun;29(3 Suppl 7):35-40. doi: 10.1053/sonc.2002.33081.
2
Interleukin-2: clinical applications.
Semin Oncol. 2002 Jun;29(3 Suppl 7):12-7. doi: 10.1053/sonc.2002.33077.
3
Prognostic factors in metastatic melanoma: a pooled analysis of Eastern Cooperative Oncology Group trials.
J Clin Oncol. 2000 Nov 15;18(22):3782-93. doi: 10.1200/JCO.2000.18.22.3782.
4
Tumor-induced immune dysfunction.
Cancer Immunol Immunother. 1999 Oct;48(7):353-62. doi: 10.1007/s002620050586.
5
Alterations in T cell receptor and signal transduction molecules in melanoma patients.
Clin Cancer Res. 1995 Nov;1(11):1327-35.
6
Hydrogen peroxide secreted by tumor-derived macrophages down-modulates signal-transducing zeta molecules and inhibits tumor-specific T cell-and natural killer cell-mediated cytotoxicity.
Eur J Immunol. 1996 Jun;26(6):1308-13. doi: 10.1002/eji.1830260620.
7
Histamine in immunotherapy of advanced melanoma: a pilot study.
Cancer Immunol Immunother. 1994 Dec;39(6):416-9. doi: 10.1007/BF01534430.
8
Histaminergic regulation of NK cells. Role of monocyte-derived reactive oxygen metabolites.
J Immunol. 1994 Dec 1;153(11):4940-7.
9
Physiology and physiopathology of the reticuloendothelial system.
Arch Intern Med. 1970 Dec;126(6):1031-52.
10
Role of histamine in natural killer cell-mediated resistance against tumor cells.
J Immunol. 1990 Dec 15;145(12):4365-70.
Zotero 插件